

**AMENDMENTS TO THE CLAIMS**

Claims 1-14 (canceled).

Claim 15 (currently amended) A method of ~~determining the risk of developing~~ diagnosing a Wnt antagonist-associated lytic bone disease characterized by ~~bone loss in a test~~ an individual, comprising said method ~~comprises the step of:~~

examining the expression level of the human homologue of Dickkopf-1 (DKK-1) protein in said ~~test~~ individual, wherein an increased expression of said protein compared to that in a normal individual indicates that said ~~test~~ individual has the ~~risk of developing~~ Wnt antagonist-associated lytic bone disease.

Claim 16-17 (canceled).

Claim 18 (previously presented) The method of claim 15, wherein said expression level is determined by enzyme-linked immunosorbent assays.

Claim 19 (currently amended) The method of claim 15, wherein said ~~test~~ individual has multiple myeloma.

Claims 20-38 (canceled).